Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Medical University of Vienna
Age
18–75
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
COHORT A:
Age 18-75 years
Histologically confirmed oligometastatic adenocarcinoma of the prostate (defined as ≤5 metastases in lymph node (LN) or bone)
Eastern Cooperative Oncology Group (ECOG) Performance Status grade 0 or 1
Planned cytoreductive radical prostatectomy
≤ 5 osseous and/or lymph node metastasis
Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation
Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, questionnaire completion and other study procedures
COHORT B:
Age 18-75 years
Histologically confirmed oligometastatic adenocarcinoma of the prostate
planned therapy with androgen deprivation therapy, and/or treatment with abiraterone acetate, and/or enzalutamide and/or docetaxel
Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation
Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, questionnaire completion and other study procedures
COHORT C:
Age 18-75 years
Histologically confirmed oligometastatic adenocarcinoma of the prostate
Metastatic castration-resistant disease
Not pre-treated with enzalutamide or abiraterone acetate
Planned therapy with abiraterone acetate, or enzalutamide
Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.
Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation
Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, questionnaire completion and other study procedures
COHORT D (control group for Cohort A):
Age 18-75 years
Histologically confirmed oligometastatic adenocarcinoma of the prostate (defined as ≤5 metastases in lymph node (LN) or bone)
Hormone-sensitive prostate cancer
Refused cytoreductive radical prostatectomy
Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation
Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, questionnaire completion and other study procedures
You may not be if
COHORT A:
HIV positive
Any contraindication for surgery
Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures.
Any contraindication for performing a PET/MRI scan
COHORTS B and C:
HIV positive
Any contraindication for tissue biopsy (if tissue biopsy is planned)
Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures.
Any contraindication for performing a PET/MRI scan
COHORT D (control group for Cohort A):
HIV positive
Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures.
Any contraindication for performing a PET/MRI scan
Clareo Health | Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer
